Retifanlimab in patients with recurrent microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) endometrial cancer: Final results from the POD1UM-101 study (Cohort H)

被引：0
|
作者：
Berton-Rigaud, D. [1 ,2 ]
Pautier, P. [3 ,4 ]
Lorusso, D. [5 ,6 ]
Gennigens, C. [7 ]
Gladieff, L. [8 ,9 ]
Kryzhanivska, A. [10 ]
Bowman, J. [11 ]
Tian, C. [12 ]
Cornfeld, M.
Van Gorp, T. [13 ]
机构：
[1] GINECO, Serv Oncol Med, St Herblain, France
[2] Inst Cancerol IOuest ICO, St Herblain, France
[3] GINECO, Dept Med, Villejuif, France
[4] Inst Gustave Roussy, Villejuif, France
[5] Fdn Policlin Univ Agostino Gemelli, Gynecol Oncol Unit, Rome, Italy
[6] Univ Cattolica Sacro Cuore, Rome, Italy
[7] Ctr Hosp Univ Sart Tilman, Oncol Gynecol Unit, Liege, Belgium
[8] GINECO, Med Oncol Dept, Toulouse, France
[9] Inst Claudius Regaud IUCT Oncopole, Toulouse, France
[10] Ivano Frankivsk Natl Med Univ, Gynecol Surg Dept, Ivano Frankivsk, Ukraine
[11] Incyte Corp, Immuno Oncol, Wilmington, DE USA
[12] Incyte Corp, Biostat, Wilmington, DE USA
[13] Univ Hosp Leuven, Leuven Canc Inst, Dept Gynaecol, Div Gynaecol Oncol, Leuven, Belgium
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1934
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
755P
引用
收藏
页码：S517 / S517
页数：1
相关论文
共 50 条
  • [1] RETIFANLIMAB (INCMGA00012) IN PATIENTS WITH RECURRENT MSI-H OR DMMR ENDOMETRIAL CANCER: RESULTS FROM THE POD1UM-101 STUDY
    Berton, Dominique
    Pautier, Patricia
    Lorusso, Domenica
    Gennigens, Christine
    Gladieff, Laurence
    Kryzhanivska, Anna
    Ranganathan, Sulabha
    Tian, Chuan
    Bourayou, Nawel
    Vergote, Ignace
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A1006 - A1006
  • [2] Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or de fi cient mismatch repair endometrial cancer: Final safety and ef fi cacy results from cohort H of the POD1UM-101 phase I study
    Berton, Dominique
    Pautier, Patricia
    Lorusso, Domenica
    Gennigens, Christine
    Gladieff, Laurence
    Kryzhanivska, Anna
    Bowman, Jill
    Tian, Chuan
    Cornfeld, Mark
    Van Gorp, Toon
    GYNECOLOGIC ONCOLOGY, 2024, 186 : 191 - 198
  • [3] Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results
    O'Malley, David M.
    Bariani, Giovani M.
    Cassier, Philippe A.
    Marabelle, Aurelien
    Hansen, Aaron R.
    Acosta, Ana De Jesus
    Miller Jr, Wilson H.
    Safra, Tamar
    Italiano, Antoine
    Mileshkin, Linda
    Yao, Lili
    Gozma, Alexander
    Jin, Fan
    Maio, Michele
    GYNECOLOGIC ONCOLOGY, 2025, 193 : 130 - 135
  • [4] Dostarlimab in advanced/recurrent (A/R) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study
    Oaknin, Ana
    Pothuri, Bhavana
    Gilbert, Lucy
    Sabatier, Renaud
    Ghamande, Sharad
    Gravina, Adriano
    Calvo, Emiliano
    Banerjee, Susana
    Mangan, Niamh
    Miller, Rowan E.
    Pikiel, Joanna
    Mirza, Mansoor R.
    Duan, Tao
    Zildjian, Sybil
    Zografos, Eleftherios
    Veneris, Jennifer
    Tinker, Anna V.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 133 - 134
  • [5] Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): The GARNET study.
    Oaknin, Ana
    Pothuri, Bhavana
    Gilbert, Lucy
    Sabatier, Renaud
    Ghamande, Sharad A.
    Gravina, Adriano
    Calvo, Emiliano
    Banerjee, Susana N.
    Miller, Rowan
    Pikiel, Joanna
    Mirza, Mansoor Raza
    Duan, Tao
    Zildjian, Sybil
    Zografos, Eleftherios
    Veneris, Jennifer Taylor
    Tinker, Anna
    Powell, Matthew A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] PEMBROLIZUMAB MONOTHERAPY FOR MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR MISMATCH REPAIR DEFICIENT (DMMR) RECURRENT GLIOMAS: RESULTS FROM THE MULTICOHORT PHASE 2 KEYNOTE-158 STUDY
    Baldini, Capucine
    Cassier, Philippe A.
    Delord, Jean-Pierre
    Simonelli, Matteo
    Touat, Mehdi
    Yao, Lili
    Duic, J. Paul
    Gozman, Alexander
    Marabelle, Aurelien
    NEURO-ONCOLOGY, 2022, 24 : 59 - 60
  • [7] Primary analysis of GEICO 120/DORA, a real-world multicentre study of dostarlimab in patients with recurrent or advanced DNA mismatch repair deficient/microsatellite instability-high (DMMR/MSI-H) endometrial cancer
    Gallego, Alejandro
    Madariaga, Ainhoa
    Estevez-Garcia, Purificacion
    Alberti, Facundo
    Carbo, Anna
    Palacio, Isabel
    Churruca, Cristina
    Galvez, Fernando
    Ortega, M. Eugenia
    Murata, Paola
    Manzano, Aranzazu
    Masvidal, Maria
    Martin-Lorente, Cristina
    Hernando, Blanca
    Lozano, Inmaculada
    Cueva, Juan F.
    Garcia-Illescas, David
    Falco, Esther
    Mendiola, Marta
    Redondo, Andres
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A182 - A182
  • [8] Pembrolizumab for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced endometrial cancer: Long-term follow-up results from KEYNOTE-158
    O'Malley, D.
    Bariani, G. M.
    Cassier, P. A.
    Marabelle, A.
    Hansen, A. R.
    De Jesus-Acosta, A.
    Miller, W. H.
    Safra, T.
    Italiano, A.
    Mileshkin, L.
    Yao, L.
    Gozman, A.
    Jin, F. J.
    Maio, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S796 - S797
  • [9] Clinicopathological and genomic characteristics of DNA Mismatch Repair-Deficient (dMMR) and microsatellite instability-high (MSI-H) resected gastric adenocarcinoma
    Zhou, J.
    Liang, B.
    Yin, M.
    Zhang, H.
    Liu, F.
    Dong, L.
    Zhang, B.
    Xu, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S921 - S922
  • [10] On pembrolizumab (Keytruda) in microsatellite instability-high/mismatch repair deficient (MSI-h/MMRd) metastatic colorectal cancer (mCRC)
    Bekaii-Saab, Tanios S.
    ONCOLOGY-NEW YORK, 2021, 35 (07): : 380 - 380
12345